Auscandoc<p>Prevalence of <a href="https://med-mastodon.com/tags/MRI" class="mention hashtag" rel="tag">#<span>MRI</span></a> lesions in men responding to a GP-led invitation for a <a href="https://med-mastodon.com/tags/prostate" class="mention hashtag" rel="tag">#<span>prostate</span></a> health check: a prospective cohort study | <a href="https://med-mastodon.com/tags/BMJOncology" class="mention hashtag" rel="tag">#<span>BMJOncology</span></a> <a href="https://bmjoncology.bmj.com/content/2/1/e000057" target="_blank" rel="nofollow noopener noreferrer" translate="no"><span class="invisible">https://</span><span class="ellipsis">bmjoncology.bmj.com/content/2/</span><span class="invisible">1/e000057</span></a> “48/303 men, had a positive screening MRI. 16/303, had a raised <a href="https://med-mastodon.com/tags/PSA" class="mention hashtag" rel="tag">#<span>PSA</span></a> density alone. 29 men (9.6%) were diagnosed with clinically significant cancer and 3 men with clinically insignificant cancer.</p><p>Two in three men with a positive MRI, and more than half of men with clinically significant disease had a PSA &lt;3 ng/mL.”</p>